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Multi-drug resistant tuberculosis (MDR-TB) represents a major health problem worldwide. 
Drug efflux and the activity of efflux transporters likely play important roles in the 
development of drug-tolerant and drug-resistant mycobacterial phenotypes. This study 
is focused on the action of a mycobacterial efflux pump as a mechanism of drug resistance. 
Previous studies demonstrated up-regulation of the TetR-like transcriptional regulator 
MSMEG_3765 in Mycobacterium smegmatis and its ortholog Rv1685c in Mycobacterium 
tuberculosis (Mtb) in acid-nitrosative stress conditions. MSMEG-3765 regulates the 
expression of the MSMEG_3762/63/65 operon, and of the orthologous region in Mtb 
(Rv1687c/86c/85c). MSMEG-3762 and Rv1687c are annotated as ATP-binding proteins, 
while MSMEG-3763 and Rv1686c are annotated as trans-membrane polypeptides, 
defining an ABC efflux pump in both M. smegmatis and Mtb. The two putative efflux 
systems share a high percentage of identity. To examine the role of the putative efflux 
system MSMEG-3762/63, we constructed and characterized a MSMEG-3763 deletion 
mutant in M. smegmatis (∆MSMEG_3763). By comparative analysis of wild type, knockout, 
and complemented strains, together with structural modeling and molecular docking 
bioinformatics analyses of the MSMEG-3763 trans-membrane protein, we define the 
protein complex MSMEG-3762/63 as an efflux pump. Moreover, we  demonstrate 
involvement of this pump in biofilm development and in the extrusion of rifampicin and 
ciprofloxacin (CIP), antimicrobial drugs used in first- and second-line anti-TB therapies.
Keywords: mycobacteria, efflux pump, antimicrobial drugs, multi drug resistance, biofilm, transmembrane 
protein, 3D structure modeling
INTRODUCTION
Tuberculosis (TB) is still considered a public health alert worldwide, with 10 million people 
falling ill and an estimated 1.4 million deaths in 2018 (Global Tuberculosis Report 2019). The 
complexity of the disease is due to many factors including the ability of Mycobacterium tuberculosis 
(Mtb), the causative agent of TB, to enter slow/non-replicating states, to remodel metabolic 
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and respiratory systems, to cause latent infection, together with 
the increasing emergence of drug-resistant Mtb (Ayabina et  al., 
2016; Dheda et  al., 2017; Bekele et  al., 2018; Gordon and 
Parish, 2018; Singh et  al., 2019). The impact of TB is also 
worsened by the high rate of Mtb infections among patients 
with chronic diseases like diabetes mellitus and HIV infection 
(Hayashi and Chandramohan, 2018; Fernandez et  al., 2020). 
Among people living with HIV, the progression from TB 
infection to disease occurs at a high rate, positioning TB as 
the leading cause of mortality in this population (Peters et  al., 
2019). Other factors are associated with more severe TB, like 
renal disease, air pollution, tobacco consumption, alcohol abuse, 
and an aging population (Hameed et al., 2018). In this scenario, 
multi-drug resistance (MDR-TB) represents a significant risk 
to global public health, and is considered one of the most 
urgent problems to address (Ayabina et  al., 2016; Dheda et  al., 
2017; Singh et al., 2019). Alternative strategies to combat MDR 
disease are underway, like the development of sensitive tests 
for early diagnosis of drug-resistant TB, or identification of 
bacterial phenotypes through drug therapy as biomarkers of 
treatment success, or therapeutic targeting of host immune 
responses (Honeyborne et  al., 2016; Wilder et  al., 2018; Thapa 
et  al., 2019; Ahmed et  al., 2020; Tsenova and Singhal, 2020). 
Studies on the molecular mechanisms involved in the acquisition 
of drug-resistant phenotypes in mycobacteria also represent an 
important strategy to combat MDR disease (Hameed et  al., 
2018; Van Camp et  al., 2020). In Mtb, drug resistance evolves 
through chromosomal mutations that impact drug degradation 
and modification or target alteration, which operate alongside 
intrinsic factors such as low cell wall permeability and an 
extensive efflux network (Singh et  al., 2019). Drug extrusion 
mediated by efflux pumps induces drug tolerance that reduces 
drug efficacy and may play a pivotal role in the development 
of resistance to anti-TB drugs (Te Brake et  al., 2018). Efflux 
pumps may also be  important for bacterial survival within 
macrophages, by detoxifying intracellular bacilli from 
acidification, toxic metal accumulation and the effects of nitrogen 
and oxygen reactive intermediates (Ehrt and Schnappinger, 2009).
Although the direct study of Mtb is necessary to understand 
pathogenic mechanisms, model systems represented by fast-
growing non-pathogenic Mycobacteria, including Mycobacterium 
smegmatis, have been used widely to highlight relevant aspects 
of Mtb physiology (Trauner et  al., 2012; Agrawal et  al., 2015). 
Previously, we  characterized the regulatory system of two 
ortholog operons, Rv1687/86/85c in Mtb and 
MSMEG_3762/63/65 in M. smegmatis, both annotated as ABC 
efflux pump systems. Cossu et  al. (2013) showed that Rv1685c 
and MSMEG_3765, coding for TetR-like regulators, were 
upregulated in acid-nitrosative stress conditions, mimicking a 
macrophage-like intracellular environment. By GFP promoter 
probe and transcriptional analyses, we  strengthened that 
observation and defined the TetR regulons. We  also showed, 
by EMSA analysis, that the recombinant purified TetR MSMEG-
3765 protein is able to bind both MSMEG_3762 and Rv1687c 
promoters, indicating binding affinity of the M. smegmatis 
protein for the Mtb regulatory region (Perrone et  al., 2017). 
This, together with the high percentage of identity between 
the two operons, suggests that the two efflux systems may 
work in an analogous way in Mtb and M. smegmatis. Based 
on these considerations and the potential importance of efflux 
in antimicrobial drug efficacy in Mtb, we  explored the role 
of the M. smegmatis MSMEG-3762/63 efflux pump. Using 
genetic manipulation, structural modeling, and molecular 
docking of MSMEG-3763, we  show that MSMEG-3762/63 is 
an efflux pump involved in the extrusion of first- and second-
line anti-TB drugs, as well as playing a role in the development 
of mycobacterial biofilms.
MATERIALS AND METHODS
Bacterial Strains and Culture Conditions
Escherichia coli TOP10 and DH5α were used for cloning. 
M. smegmatis mc2155 was used throughout this work. The 
E. coli strains were grown in Luria-Bertani (LB) broth, while 
M. smegmatis was cultured in Middlebrook 7H9 broth (Difco) 
containing 10% oleic acid-albumin-dextrose-catalase supplement 
(Becton Dickinson) and 0.05% Tween 80. All strains were 
grown at 37°C with shaking at 200  rpm. Hygromycin (200  μg 
ml−1 for E. coli and 100  μg ml−1 for M. smegmatis), kanamycin 
(50  μg ml−1 for E. coli and 25  μg ml−1 for M. smegmatis), 
5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside (Xgal 50 μg 
ml−1) and sucrose (2% w/v) were used for selection or screening 
as appropriate. Ciprofloxacin, Norfloxacin, and Ofloxacin stock 
solutions (10  mg/ml−1) were prepared in NaOH 1  M and 
Rifampicin stock solution (10 mg/ml−1) was prepared in methanol. 
Mycobacterial biofilms were grown in Sauton medium (0.5  g 
KH2PO4, 0.5  g MgSO4 7H2O, 2.0  g citric acid, 0.05  g ferric 
ammonium citrate, 60  ml glycerol, 4.0  g asparagine, 0.1  ml 
ZnSO4 1% solution, distilled water up to 1,000 ml, and pH 7.4).
Construction of the Mycobacterium 
smegmatis (ΔMSMEG_3763) Deletion 
Mutant
Primer sequences and plasmids are listed in 
Supplementary Tables S1, S2, respectively. The M. smegmatis 
(ΔMSMEG_3763) mutant strain, carrying an in frame deletion 
in MSMEG_3763, was isolated using a two-step homologous 
recombination strategy (Parish et al., 1999). A 806 bp fragment 
(up), containing the upstream flanking regions of MSMEG_3763 
was PCR-amplified from M. smegmatis mc2155 genomic DNA 
using the forward upMS3763f and reverse upMS3763r primers. 
The amplified fragment (up) was cloned into HindIII and 
KpnI restriction sites of p2NIL, yielding the pBD01 plasmid. 
A 825 bp fragment (dw), containing the downstream flanking 
regions of MSMEG_3763, was PCR-amplified from M. smegmatis 
mc2155 genomic DNA using the forward dwMS3763f and 
reverse dwMS3763r primers. The amplified fragment (dw) 
was cloned into KpnI and PacI restriction sites of pBD01, 
yielding the pBD02 plasmid. To obtain the suicide delivery 
vector pBD03, the pGOAL19 cassette was cloned into the 
PacI restriction site of the pBD02 plasmid. pBD03 was 
electroporated into M. smegmatis mc2155 and single crossover 
events (SCOs), positive in the Xgal screening and resistant 
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to kanamycin and hygromycin, were verified by colony PCR. 
Among the positive SCOs, a single colony was streaked onto 
fresh media without selection, and incubated at 37°C for 
5  days to allow the second recombination event to occur, 
before selection on plates containing sucrose and Xgal. The 
white sucrose-resistant colonies were screened for kanamycin 
and hygromycin sensitivity, and then analyzed by colony PCR 
to confirm that a second recombination event had occurred, 
yielding a deletion of 771  bp in the coding region of 
MSMEG_3763. One positive clone was chosen for further 
experiments and herein named M. smegmatis (ΔMSMEG_3763). 
The in-frame deletion event in M. smegmatis (ΔMSMEG_3763) 
was verified by sequencing.
Construction of the Mycobacterium 
smegmatis (ΔMSMEG_3763 pBD04) 
Complemented Strain
To complement the gene-inactivating mutation in M. smegmatis 
(ΔMSMEG_3763), a DNA fragment containing the 770  bp 
coding sequence of MSMEG_3763 (including start and stop 
codons) was PCR-amplified from M. smegmatis mc2155 with 
forward cMS3763f and reverse cMS3763Salr primers 
(Supplementary Table S2). The forward primer included an 
optimized Shine–Dalgarno sequence. The resulting 805  bp 
fragment was cloned into the EcoRI-SalI sites of pMV306hsp 
(Addgene#26155) to obtain pBD04, carrying the MSMEG_3763 
gene under the control of the Mycobacterium bovis BCG hsp60 
promoter. The recombinant plasmid pBD04 was verified by 
PCR and sequencing (Microgem Laboratory Research). pBD04 
was electroporated into M. smegmatis (ΔMSMEG_3763) to 
generate the complemented M. smegmatis (ΔMSMEG_3763 
pBD04) strain. Recombinant clones were selected using 
kanamycin, and the presence of pBD04 was verified by plasmid 
extraction followed by PCR analysis.
Ethidium Bromide Efflux Pump Inhibition 
Assay
Efflux pump activity was determined using ethidium bromide 
(EtBr) as previously described (Rodrigues et  al., 2013). 
Mycobacterium smegmatis strains were grown in 7H9/OADC 
medium at 37°C to an OD600 of 0.6 (corresponding to 108 CFU 
ml−1), the pellet washed and resuspended in PBS supplemented 
with 0.05% Tween80 and EtBr solution to final concentration 
of 2  μg ml−1. Aliquots of 195.5  μl of the bacterial suspension 
were added to 96 well microtitre plate containing 4.5  μl of 
water or 4.5  μl of verapamil (VPL) to a final concentration 
of 250 μg ml−1. The assay was conducted at 37°C in a Promega 
GloMax® Discover Microplate Reader using the excitation and 
emission wavelengths of 520 nm and 560–640 nm, respectively. 
Fluorescence data was acquired every 60  s for 90 min at 37°C. 
Fluorescence values were expressed as percentage increase with 
respect to the value of each sample at 1  min. EtBr and VPL 
were used at ¼ the M. smegmatis minimum inhibitory 
concentration (MIC) in order not to compromise the cellular 
viability, as confirmed by c.f.u. counting. Each experiment was 
repeated in triplicate.
MIC Determination
The MIC determination protocol was adapted from 
Agrawal et  al. (2015). In brief, wells of a 96 well microtitre 
plate were filled with 50  μl 7H9 media except for the first 
column. Double of the required drug concentration was prepared 
and 100  μl volumes were added to the first column. This was 
diluted to reach the desired concentration of rifampicin, or 
serially diluted to halve the concentration by mixing with media 
only in the subsequent wells to the penultimate column for 
CIP. No drug was added to the last column as a no antibiotic 
control. The M. smegmatis strains were grown in replicates in 
7H9 medium to an OD600 of 0.6, diluted 1,000 times 
(corresponding to 105  CFU ml−1; Supplementary Figure S1), 
and 50  μl of the diluted culture was added to each well. The 
plate was sealed with parafilm to avoid drying of the cultures, 
and incubated with mild shaking (100  rpm) at 37°C for 40  h, 
followed by addition of 30  μl Sigma Resazurin sodium salt 
dye (filter sterilized, 0.2  mg ml−1 final concentration) to each 
well and incubation for a further 6  h before imaging. For EtBr 
and VPL MIC determination, 20 μl of Promega CellTiter-Blue® 
was used as indicator. MICs were determined as the values of 
the first well showing no growth as indicated by color change.
Biofilm Formation and Quantification 
Assay
Biofilm formation assay was performed as previously described 
but with some modifications (O’Toole 2011). Bacterial cultures 
were grown in 7H9/ADC 0.05% Tween80 medium. The well-
grown primary cultures (~OD600 1.5) of wild-type, M. smegmatis 
(ΔMSMEG_3763) and M. smegmatis (ΔMSMEG_3763 pBD04) 
strains were washed twice with Sauton medium to remove 
Tween80. The cultures were diluted 1:500 to inoculate 7  ml 
Sauton medium in 60  mm diameter polystyrene Petri dishes. 
Petri dishes were incubated for 3–6 days at 37°C in a humidified 
incubator, and the formation of surface pellicles was monitored. 
Quantification of biofilm was performed as follows: well-grown 
primary cultures (~OD600 1.5) were washed with Sauton medium 
and diluted to a final OD600 of 0.05  in the same medium, then 
distributed into 96-well polystyrene microtitre plates and incubated 
at 37°C in a humidified incubator for 4–7  days. Each well 
received an inoculum of 200  μl. After incubation, contents of 
the wells were aspirated out by syringe and the wells were 
washed with sterile water. The wells were then stained for 
15  min, adding 300  μl 1% Crystal Violet (w/v) solution to 
each well. The stain was removed, washing the plate with sterile 
water, and plates were left to air dry. 300  μl 80% ethanol was 
added to each stained well and the plates were incubated for 
15  min at room temperature. The content of each well was 
mixed by pipetting, and 200  μl transferred to an optically clear 
flat-bottom 96-well plate. Optical density (OD) was measured 
at 550  nm using a Biotek Synergy HT plate reader.
3D Structure Modeling
Amino acid sequences were retrieved and analyzed with ExPASy 
tools using the MSMEG_3763 gene sequence as input. The 
MSMEG-3763 aggregation profile was evaluated using the 
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AGGRESCAN server and the presence of putative transmembrane 
helices predicted by the TMHMM server on the basis of the 
amino acid sequence (Krogh et al., 2001). The three-dimensional 
(3D) structure of MSMEG-3763 was predicted using the I-TASSER 
server (Interactive Threading ASSEmbly Refinement; Roy et al., 
2010). I-TASSER is a computational structure modeling method 
that uses a combinatorial approach of comparative modeling, 
threading, and ab initio modeling (Roy et al., 2010). In particular, 
the structure predictions by I-TASSER rely on template proteins 
with known structures obtained from databases and the prediction 
procedures are based on matching the query sequence against 
a non-redundant sequence database. According to I-TASSER 
criteria, the selection of the representative 3D model was 
performed by evaluating the C-score. This latter parameter is 
a scoring function based on the relative clustering structural 
density and the consensus significance score of the multiple 
threading templates. The C-score is usually in the range from 
−5 to 2, where a score of higher value indicates a predicted 
model with a high confidence and vice versa. Additionally, 
the quality of the selected model was further evaluated using 
PROCHECK and MolProbity (Laskowski et  al., 1996; Davis 
et al., 2007). The selected 3D model was visualized using PyMol 
(The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, 
LLC) and Chimera (Pettersen et  al., 2004). The secondary 
structure elements were identified by DSSP (Hess et  al., 2008; 
Joosten et al., 2011; Huang and MacKerell, 2013). The membrane 
protein modeling of MSMEG-3763 was performed using a 
two-step procedure. First, the protein was dissolved in dipalmitoyl 
phosphatidylcholine (DPPC) phospholipid bilayer by GROMACS 
(Hess et  al., 2008) using the CHARMM36 force field (Huang 
and MacKerell, 2013). The protein was inserted into the membrane 
using the structural information obtained as reported above 
by TMHMM server. Finally, in order to define the correct 
orientation and position of MSMEG-3763 inside the membrane 
a minimization protocol was applied.
Molecular Docking Studies
Molecular docking studies of rifampicin and ciprofloxacin with 
MSMEG-3763 were conducted using EAdock algorithm 
implemented in the Swissdock server (Grosdidier et  al., 2011). 
The molecular docking protocol involved the preparation of 
MSMEG-3763 and ligand structures. In particular, for the protein 
the predicted 3D model was used as the reference structure, 
whereas the rifampicin and ciprofloxacin structures were 
downloaded from Protein Data Bank (PDB) database. In accord 
with the docking protocol, all residues of the protein were held 
fixed and a binding pocket was not defined. The docking 
procedure was validated by comparing the binding affinity values 
estimated for the ciprofloxacin/MSMEG-3763 (-5.9  kcal/mol) 
and rifampicin/MSMEG-3763 (-6.1  kcal/mol) complexes with 
that obtained from the ofloxacin/MSMEG-3763 (-4.2  kcal/mol) 
model. The binding affinity values were obtained for each docking 
model by using PRODIGY webserver.1 All docked poses were 
visualized and analyzed using Chimera (Pettersen et  al., 2004).
1 https://bianca.science.uu.nl/prodigy/
RESULTS
Deletion of MSMEG_3763 Reduces the 
Ability of Mycobacterium smegmatis to 
Efflux Etbr
The M. smegmatis (ΔMSMEG_3763) mutant strain, carrying a 
771  bp deletion in the coding region of MSMEG_3763, and its 
isogenic M. smegmatis (ΔMSMEG_3763 pBD04) complemented 
strain were constructed to characterize the function of the putative 
MSMEG-3762/63 mycobacterial efflux pump. The growth rate 
of the mutant and complemented strains were comparable to 
that of wild type in standard laboratory conditions (data not shown).
Ethidium Bromide accumulation is a well-established method 
to monitor efflux activities in bacteria. The assay was used to 
assess the role of MSMEG-3763 as a component of the putative 
efflux pump by measuring differences in EtBr accumulation 
between wild type M. smegmatis (wt), deletion mutant 
(ΔMSMEG_3763), and complemented (ΔMSMEG_3763 pBD04) 
strains in the absence and presence of VPL, an efflux pump 
inhibitor (EPI). First, MICs of EtBr and VPL were determined 
as 8  μg ml−1 and 900  μg ml−1 for EtBr and VPL, respectively 
(data not shown). The efflux inhibition assays were conducted 
using concentrations that did not affect mycobacterial viability 
(¼ MICs). As expected, the M. smegmatis (ΔMSMEG_3763) 
mutant strain showed higher EtBr accumulation compared to 
the wild type and the complemented strains (Figure  1A). When 
the bacterial cultures were exposed to both EtBr and VPL, increased 
EtBr accumulation was observed for the three strains over the 
same incubation time. Once again, EtBr accumulation was higher 
for the mutant compared to the wild type and the complemented 
strains (Figure  1B), demonstrating that loss of MSMEG-3763 
reduced the ability of mycobacteria to remove EtBr, and suggesting 
that this complex possessed efflux pump activity.
Deletion of MSMEG_3763 Increases the 
Sensitivity of Mycobacterium smegmatis 
to Antimicrobial Drugs
In order to verify the involvement of the MSMEG-3762/63 
efflux pump in the removal of antimicrobial compounds used 
in anti-TB therapy, the MICs for first- and second-line anti-TB 
drugs were determined using the Resazurin Reduction Microtiter 
Assay (REMA). The MIC of rifampicin was lower (2  μg ml−1) 
for M. smegmatis (ΔMSMEG_3763) compared to M. smegmatis 
(wt; 3 μg ml−1; Figure  2A). As expected, the MIC of rifampicin 
for complemented M. smegmatis (ΔMSMEG_3763 pBD04) was 
the same as that observed for the wild type strain. The loss 
of MSMEG-3763 did not change the efficacy of other first-line 
antibiotics, isoniazid, and pyrazinamide (data not shown). The 
MICs of second-line TB antibiotics were also determined. 
An increase in sensitivity of M. smegmatis (ΔMSMEG_3763) 
to ciprofloxacin was observed. The MICs of ciprofloxacin 
for M. smegmatis (wt) and complemented M. smegmatis 
(ΔMSMEG_3763 pBD04) were (0.25  μg ml−1), while the 
MIC for M. smegmatis (ΔMSMEG_3763) was 0.12  μg/ml−1 
(Figure  2B). No difference in MIC was observed for other 
second-line anti-TB drugs, NOR or ofloxacin (data not shown). 
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A
B
FIGURE 1 | Accumulation of ethidium bromide (EtBr) over time in the absence (A) and presence (B) of verapamil (VPL) in Mycobacterium smegmatis (wt – yellow), 
deletion (ΔMSMEG_3763 – light blue) and complemented (ΔMSMEG_3763 pBD04 – dark blue) strains. The assay was conducted at 37°C. All the experiments were 
performed three times in triplicate.
A B
FIGURE 2 | (A) Minimum inhibitory concentration (MIC) determination of rifampicin for (1) M. smegmatis wt (3 μg ml-1), (2) M. smegmatis (ΔMSMEG_3763; 2 μg 
ml-1), and (3) M. smegmatis (ΔMSMEG_3763 pBD04; 3 μg ml-1); (B) MIC determination of ciprofloxacin (CIP) for M. smegmatis wt (0.25 μg ml-1), M. smegmatis 
(ΔMSMEG_3763; 0.12 μg ml-1), and M. smegmatis (ΔMSMEG_3763 pBD04; 0.25 μg ml-1). MICs were determined by Resazurin Reduction Microtiter 
Assays (REMA). All experiments were performed three times in triplicate.
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Thus, abrogation of MSMEG-3762/63 efflux pump function increased 
mycobacterial drug sensitivity to both rifampicin and ciprofloxacin.
MSMEG-3763 Contains Predicted 
Transmembrane Helices
A bioinformatic analysis of the MSMEG-3763 protein based 
on its primary aa sequence was performed. The aggregation 
profile of the protein was determined using AGGRESCAN 
and TMHMM servers (Figure  3A), showing that the regions 
spanning residues 29–35, 37–48, 60–71, 73–83, 121–135, 141–165, 
182–190, and 230–248 are clearly characterized by high 
aggregation prone sequences. Further analysis using the server 
TMHMM suggested that, in the regions showing high aggregation 
propensity, the protein may form transmembrane helices 
(Figure  3B).
3D Modeling of MSMEG-3763 Reveals a 
Channel Forming Structure
To better understand the functional proprieties of MSMEG-3763 
a detailed description of the structural features is required. 
Therefore, to elucidate the molecular details of the protein, 
we  performed 3D modeling of the structure using I-TASSER. 
The computational modeling of MSMEG-3763 generated five 
models with C-scores ranging from −4.36 to 0.29. The 3D 
model with the highest c-score was used as a reference for the 
structural analysis. Additionally, the good quality of the selected 
3D model was confirmed by evaluating the structural statistics 
(Supplementary Figure S2A) and the Ramachandran plots 
(Supplementary Figure S2B) respectively, obtained by analyzing 
the predicted model using the software MolProbity (Davis et al., 
2007), with 86 and 11% of aa-residues situated in most favorable 
(MF) and allowed regions (AR), and PROCHECK (Laskowski 
et  al., 1996), with 84 and 13% aa-residues situated in MF and 
AR, respectively. The 3D structural model of MSMEG-3763 
(Figure  3C) indicates that the protein presents as a globular 
fold composed of 10 α-helices (A = 10–27, B = 29–47, C = 60–91, 
D  =  94–101, E  =  106–136, F  =  143–169, G  =  172–188, 
H  =  201–207, I  =  213–223, and L  =  232–257) joined by short 
non-helical regions that provide a rigid structural framework. 
In particular, the hydrophobic portion of the protein is a typical 
helix bundle composed of six α-helices (Figure  3C, in red) 
that likely forms a channel inside the membrane. As proposed 
by the model reported in Figure  3D, the hydrophilic portions, 
according to TMHMM predictions, probably correspond to the 
outer and the cytosolic regions of the protein. Therefore, structural 
modeling of the putative transmembrane component of the 
MSMEG-3762/63 efflux pump predicts a structure suited 
to purpose.
Molecular Docking Analysis Suggests That 
Rifampicin and Ciprofloxacin Are Ligands 
of MSMEG-3763
To gain structural insights into the interaction between rifampicin 
and ciprofloxacin compounds and the membrane protein 
MSMEG-3763 (Figure 4A), we performed a series of molecular 
docking studies that represent a powerful technique for studying 
protein-ligand complexes. In particular, molecular docking aims 
to predict at atomic level the binding mode (i.e., position and 
orientation) and affinity of a complex formed by two or more 
constituent molecules with known structures. The three-
dimensional model of protein-ligand complexes of MSMEG-3763 
was generated using the EAdock algorithm (Figure  4B). The 
optimized structure of the ciprofloxacin/MSMEG-3763 complex 
indicated that the recognition mechanism of ciprofloxacin by 
MSMEG-3763 is principally mediated by the residues Phe107, 
Leu157, Leu161, Val182, Pro185, Leu188, Leu189, Trp205, Val206, Ala209, 
Leu210, Pro211, Phe242, Leu245, Ala246, Leu249 forming a shallow 
hydrophobic pocket on the surface of MSMEG-3763 (Figure 4C). 
Instead, for the rifampicin/MSMEG-3763 complex (Figure 4D) 
the molecular docking structure predicted that rifampicin binds 
into a hydrophobic cleft on the surface of MSMEG-3763 formed 
by Phe107, Leu110, Ala111, Gly114, Val156, Val159, Gly160, Val244, Leu247, 
and Ala251. These docking results therefore suggest that this 
efflux pump has the capacity to bind, and potentially export, 
the antimicrobial drugs rifampicin and ciprofloxacin. To validate 
the docking protocol applied to obtain the structural model 
of ciprofloxacin/MSMEG-3763 and rifampicin/MSMEG-3763 
complexes, we  estimated for both models the binding affinity 
and then compared these values with that estimated for the 
ofloxacin/MSMEG-3763 model (Supplementary Figure S3) 
obtained using the same docking parameters. Notably, no 
difference in MIC of ofloxacin was observed for M. smegmatis 
wt and ∆3763 mutant strain. The comparison of the binding 
affinity values (ciprofloxacin/MSMEG-3763  =  -5.9  kcal/mol; 
rifampicin/MSMEG-3763 = -6.1 kcal/mol; and ofloxacin/MSMEG-
3763  =  -4.2  kcal/mol) clearly indicates that the formation of 
ciprofloxacin/MSMEG-3763 and rifampicin/MSMEG-3763 
complexes is favored with respect to the ofloxacin/MSMEG-
3763 complex, confirming the MIC data.
These findings demonstrate that the applied docking protocol 
allows a structural model for ciprofloxacin and rifampicin 
binding to be  obtained, providing a reasonable description of 
the molecular determinants involved in the recognition 
mechanism of MSMEG-3763 for both compounds.
Inactivation of MSMEG-3763 Inhibits 
Biofilm Formation
Bacterial efflux pumps have roles in many physiological functions 
that influence pathogenicity besides drug export, including 
biofilm development. To test if the absence of MSMEG-3763 
affected the ability to form a mycobacterial biofilm, a comparative 
analysis of the three strains was performed. Pellicles formed 
by M. smegmatis (wt) were observed on the surface after 3 days 
of incubation and continued to develop up to the last day 
of observation (day 6; Figure  5A). The M. smegmatis 
(ΔMSMEG_3763) deletion mutant also formed a biofilm, but 
the reticulated appearance associated with formation of the 
extracellular matrix was not observed on the surface of the 
liquid growth medium. This observation was further confirmed 
by a crystal violet quantification of the biofilms (Figure  5B). 
The amount of biofilm formed by the efflux pump mutant M. 
smegmatis (ΔMSMEG_3763) was reduced from 33–61%, 
depending on the day of sampling, compared with the wild 
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FIGURE 3 | (A) The MSMEG-3763 protein aggregation profile using the AGGRESCAN server; (B) prediction of transmembrane helices by the TMHMM server; 
(C) MSMEG-3763 protein 3D model structure, calculated using the I-TASSER algorithm, where the six α-helices that likely form a channel inside the membrane are 
shown in red; (D) A proposed model placing MSMEG-3763 in the lipid double layer of the cytosolic membrane, according to TMHMM server modeling.
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type. As expected, the ability to form a biofilm was restored 
nearly to wild type levels in the M. smegmatis (ΔMSMEG_3763 
pBD04) complemented strain (Figure 5B). Loss of efflux function 
through MSMEG-3762/63 therefore interferes with biofilm 
development, influencing mycobacterial interactions with the 
environment that may affect pathogenicity.
DISCUSSION
Multi-drug resistance of an increasing number of pathogens 
represents a growing health problem worldwide. This is particularly 
urgent for diseases like tuberculosis, mainly caused by Mtb, 
or nosocomial infections caused by opportunistic pathogens 
such as Staphylococcus aureus, Pseudomonas aeruginosa, and 
Acinetobacter baumannii (Dheda et al., 2017; Botelho et al., 2019; 
Guo et al., 2020; Moubareck and Halat, 2020). Antibiotic resistance 
may be conferred through different mechanisms, such as antibiotic 
degradation or modification, receptor alteration, or antibiotic 
efflux mediated by membrane transport systems (Machado et al., 
2017; Singh et al., 2019; Van Camp et al., 2020). Efflux transporters 
are a serious problem to the efficacy of antimicrobial drugs as 
they confer to bacteria the capacity to rapidly export drugs and 
to evade current drug therapies (Alcalde-Rico et  al., 2016; Du 
et al., 2018). For instance, in Staphylococcus aureus, over-expression 
of efflux pumps has been associated with high levels of resistance 
to many antibiotics (Hassanzadeh et  al., 2020).
Although efflux pumps are mostly studied for their role in 
antibiotic resistance, there is growing evidence of their involvement 
in a variety of bacterial behaviors related to phenotypes associated 
with virulence, including biofilm development and quorum 
sensing-dependent expression of virulence factors (Piddock, 
2006; Alcalde-Rico et  al., 2016; Alav et  al., 2018; Du et  al., 
2018). For instance, in P. aeruginosa, where a high percentage 
of virulence genes are under the control of different quorum 
sensing systems, the involvement of efflux pumps in extruding 
intercellular signal molecules or their precursors, as in the case 
of the MexAB, MexGHI, and MexEF efflux systems, has been 
reported, in addition to roles in biofilm development and 
secretion of host-produced antimicrobial compounds (Minagawa 
et  al., 2012). Efflux pumps are also emerging as functionally-
relevant in pathogen-host interactions. Pasqua et  al. (2019) 
reported that the EmrKY efflux pump is required for survival 
of Shigella in the macrophage environment, highlighting for 
the first time the key role of an efflux pump during the Shigella 
invasive process. Furthermore, the ABC family efflux pump 
MacAB is required for survival of Salmonella enterica serovar 
Typhimurium inside the macrophage environment, where they 
are exposed to ROS; indeed, deletion mutants of macAB genes 
showed weakened intracellular replication within macrophages 
and an impaired growth in the inflamed intestine (Bogomolnaya 
et  al., 2013; Alcalde-Rico et  al., 2016).
In Mtb, Rv1685c, coding for a TetR-like protein, and its 
ortholog MSMEG_3765 in M. smegmatis were found to 
A B
C D
FIGURE 4 | (A) Secondary and tertiary organization of MSMEG-3763 as proposed by the predicted 3D model. (B) Overlay of the three-dimensional (3D) models 
predicted by molecular docking studies of the protein-ligand complexes of MSMEG-3763 with ciprofloxacin (cyan) and rifampicin (magenta). Mapping of the 
residues of MSMEG-3763 involved in the interaction with ciprofloxacin (orange; C) and rifampicin (light green; D).
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be  upregulated in acid-nitrosative stress conditions, mimicking 
the macrophage environment (Cossu et  al., 2013). Members 
of the TetR family of transcriptional regulators are widespread 
among bacteria, especially in microorganisms exposed to 
environmental stresses, being involved in the control of many 
cellular functions, including efflux pump activity (Balhana et al., 
2015). We  have previously demonstrated that in M. smegmatis, 
the TetR-like protein MSMEG-3765 (TetR3765) regulates 
expression of its own operon, coding for two other proteins 
annotated as components of an ABC efflux pump, and that 
the recombinant purified TetR3765 protein is able to bind both 
MSMEG_3762/63/65 and Rv1687/86/85c upstream sequences, 
indicating binding affinity of the M. smegmatis protein for the 
Mtb regulatory region (Perrone et  al., 2017). These results 
suggested that the same regulatory system exists for expression 
of the putative MSMEG-3762/63 and Rv1687/86c efflux pumps, 
which share a high level of amino acid sequence identity.
Here, we used isogenic M. smegmatis deletion (ΔMSMEG_3763) 
and complemented M. smegmatis (ΔMSMEG_3763 pBD04) 
strains to characterize the MSMEG-3762/63 efflux pump. The 
role of this gene cluster annotated as efflux pump components 
was confirmed by EtBr accumulation assay, where loss of 
the system resulted in faster accumulation of EtBr in the 
mycobacterial cell. A comparative analysis of wild type, deletion 
and complemented strains revealed that the MSMEG-3762/63 
efflux system is involved in biofilm development, a phenotype 
associated to virulence and demonstrated to depend upon activity 
of efflux pumps in various pathogens (Alav et  al., 2018).
Using structural modeling tools, we show that MSMEG-3763 
contains several regions with high aggregation propensity that 
may form transmembrane helices. The predicted three-
dimensional structure indicates that the protein presents as a 
globular fold composed of 10 α-helices. Moreover, the structural 
data demonstrated that the fold is further stabilized by 
hydrophobic interactions between residues of the six central 
α-helices that show a typical helix bundle topology, that likely 
has a crucial role in the formation of a trans-membrane channel.
Efflux systems contribute to the intrinsic resistance of bacteria 
to antimicrobial drugs (Singh et al., 2019). In Mtb, up-regulation 
of Rv0194 and mmpL5, coding for efflux pump components, 
occurred in a higher number of rifampicin-resistant compared 
to rifampicin-susceptible clinical isolates, highlighting a potential 
role of these efflux systems in the development of drug resistance 
in patients (Narang et  al., 2019). Therefore, we  determined 
the sensitivity of M. smegmatis (∆MSMEG_3763) to anti-TB 
drugs, which indicated that the MSMEG-3762/63 complex is 
A
B
FIGURE 5 | (A) A top-down view of mycobacterial pellicle biofilms after 3–6 days growth in detergent-free Sauton medium with (1) M. smegmatis wild type, 
(2) deletion (ΔMSMEG_3763), and (3) complemented (ΔMSMEG_3763 pBD04) strains. In contrast to the wild type, the M. smegmatis (ΔMSMEG_3763) mutant 
strain formed an untextured biofilm; normal pellicle formation was restored upon complementation. All the experiments were performed three times in triplicate; 
(B) Crystal violet quantification of biofilms of M. smegmatis wild type (wt – dark gray), deletion (ΔMSMEG_3763 – black), and complemented (ΔMSMEG_3763 
pBD04 – light gray) strains. The biofilm mass formed at days 4, 5, and 6 was quantified spectrophotometrically at 550 nm after crystal violet staining. All the 
experiments were performed three times in triplicate. Error bars indicate the standard deviation of the mean values. *p < 0.001.
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involved in the efflux of rifampicin and ciprofloxacin, first- and 
second-line anti-TB drugs, respectively. Based on these results, 
we mapped the structural details regulating the complex formation 
between MSMEG-3763 and the two drug ligands by 
computational docking. In the case of ciprofloxacin, the molecular 
docking studies reveal that complex formation is controlled 
by a shallow hydrophobic cleft formed by residues located in 
the α-helices E, F, G, H, and L; while for rifampicin the binding 
mechanism is suggested to be principally modulated by residues 
situated in the regions belonging and surrounding the E, F, 
and L α-helices.
Efflux pumps represent important therapeutic targets in the 
treatment of MDR infectious diseases, included TB, evidenced 
by recent inhibition of the essential mycobacterial efflux pump, 
EfpA (Johnson et  al., 2019, 2020). Indeed, the possibility of 
EPIs as candidate molecules to treat TB is widely studied 
(Kumar et  al., 2016). Rational drug design alongside a deeper 
understanding of efflux pump physiology and structure will 
lead to new more effective therapeutic strategies for MDR 
disease (Reza et  al., 2019; Zarate et  al., 2019).
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